Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease
Journal of the American Heart Association · 2024
DOI: 10.1161/jaha.123.032971 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Ixchel Lima Posada und 9 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité Paris France. Hauptthemen laut MEDLINE: Mineralocorticoid Receptor Antagonists, Renal Insufficiency, Chronic, Naphthyridines, Ventricular Dysfunction, Left. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The mineralocorticoid receptor plays a significant role in the development of chronic kidney disease (CKD) and associated cardiovascular complications. Classic steroidal mineralocorticoid receptor antagonists are a therapeutic option, but their use in the clinic is limited due to the associated risk of hyperkalemia in patients with CKD. Finerenone is a nonsteroidal mineralocorticoid receptor antagonist that has been recently investigated in 2 large phase III clinical trials (FIDELIO‐DKD [Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease] and FIGARO‐DKD [Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease]), showing reductions in kidney and cardiovascular outcomes. Methods and Results We tested whether finerenone improves renal and cardiac function in a preclinical nondiabetic CKD model. Twelve weeks after 5/6 nephrectomy, the rats showed classic signs of CKD characterized by a reduced glomerular filtration rate and increased kidney weight, associated with left ventricular (LV) diastolic dysfunction and decreased LV perfusion. These changes were associated with increased cardiac fibrosis and reduced endothelial nitric oxide synthase activating phosphorylation (ser 1177). Treatment with finerenone prevented LV diastolic dysfunction and increased LV tissue perfusion associated with a reduction in cardiac fibrosis and increased endothelial nitric oxide synthase phosphorylation. Curative treatment with finerenone improves nondiabetic CKD‐related LV diastolic function associated with a reduction in cardiac fibrosis and increased cardiac phosphorylated endothelial nitric oxide synthase independently from changes in kidney function. Short‐term finerenone treatment decreased LV end‐diastolic pressure volume relationship and increased phosphorylated endothelial nitric oxide synthase and nitric oxide synthase activity.
Conclusions
We showed that the nonsteroidal mineralocorticoid receptor antagonist finerenone reduces renal hypertrophy and albuminuria, attenuates cardiac diastolic dysfunction and cardiac fibrosis, and improves cardiac perfusion in a preclinical nondiabetic CKD model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité Paris France.
- Univ Rouen Normandie, INSERM EnVI UMR 1096 Rouen France.
- Department of Medicine University of Michigan Medicine Ann Arbor MI.
- Cardiovascular Precision Medicines, Research and Early Development, Pharmaceuticals, Bayer AG Wuppertal Germany.
- Université de Lorraine, INSERM Centre d'Investigations Cliniques-Plurithématique 1433, UMR 1116, CHRU de Nancy, French-Clinical Research Infrastructure Network (F-CRIN) INI-CRCT Nancy France.
ORCID-Profile: Ixchel Lima Posada, Matthieu Soulié, Yohan Stephan, Roberto Palacios Ramirez, Benjamin Bonnard, Lionel Nicol, Bertram Pitt, Peter Kolkhof, Paul Mulder, Frederic Jaisser
Zitieren
APA
Lima Posada, I., Soulié, M., Stephan, Y., Palacios Ramirez, R., Bonnard, B., Nicol, L., Pitt, B., Kolkhof, P., Mulder, P., & Jaisser, F. (2024). Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.032971
Vancouver
Lima Posada I, Soulié M, Stephan Y, Palacios Ramirez R, Bonnard B, Nicol L, et al. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.032971
BibTeX
@article{LimaPosada2024,
author = {Lima Posada, Ixchel and Soulié, Matthieu and Stephan, Yohan and Palacios Ramirez, Roberto and Bonnard, Benjamin and Nicol, Lionel and Pitt, Bertram and Kolkhof, Peter and Mulder, Paul and Jaisser, Frederic},
title = {Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease},
journal = {Journal of the American Heart Association},
year = {2024},
doi = {10.1161/jaha.123.032971}
}
EUVIMED